Claims for Patent: 9,446,145

Summary for Patent: 9,446,145

Title:	Curcumin-antibody conjugates as anti-cancer agents
Abstract:	The invention relates to curcumin derivatives having the formula I: wherein: Z represents: H.sub.3CO A represents --CH.sub.2--CH.sub.2-- or --CH.dbd.CH--; L represents --C(O)--(NH).sub.n1--R--(NH).sub.n2--C(O)--; R represents a saturated or unsaturated, branched or unbranched hydrocarbyl chain having a minimum of 3 carbon atoms in the chain; wherein the maximum number of carbon atoms in the chain is 24; and wherein the carbon atoms of the chain can be replaced by at least one heteroatom, wherein the heteroatoms are independently --O-- or --NH.sub.2--, with the proviso that each heteroatom is separated from each other heteroatom by at least two carbon atoms; n1 and n2 independently represent 0 or 1; and Y represents an antibody that binds specifically to a target antigen of a tumor cell. The invention further relates to methods of method of inhibiting the growth of tumors in a human by administering an effective amount of the curcumin derivative, and to methods of producing the curcumin derivative. ##STR00001##
Inventor(s):	Banerjee; Probal (Staten Island, NY), Krishnaswami; Raja (Staten Island, NY)
Assignee:	RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (New York, NY)
Application Number:	13/513,348
Patent Claims:	1. A curcumin derivative having the formula I: Z-L-Y (I) wherein: Z represents: ##STR00006## A represents --CH.sub.2--CH.sub.2-- or --CH.dbd.CH--; L represents --C(O)--(NH).sub.n1--R--(NH).sub.n2--C(O)--; R represents a saturated or unsaturated, branched or unbranched hydrocarbyl chain having a minimum of 3 carbon atoms in the chain; wherein the maximum number of carbon atoms in the chain is 24; and wherein the carbon atoms of the chain can be replaced by at least one heteroatom, wherein the heteroatoms are independently --O-- or --NH.sub.2--, with the proviso that each heteroatom is separated from each other heteroatom by at least two carbon atoms; n1 and n2 independently represent 0 or 1; and Y represents a CD68 antibody. 2. A curcumin derivative according to claim 1, wherein A represents --CH.dbd.CH--. 3. A curcumin derivative according to claim 1, wherein n1 and n2 are 0. 4. A curcumin derivative according to claim 1, wherein R represents a saturated, unbranched hydrocarbyl chain. 5. A curcumin derivative according to claim 1, wherein R represents a saturated, unbranched hydrocarbyl chain having a minimum of 3 and a maximum of 8 carbon atoms. 6. A curcumin derivative according to claim 1, wherein a lysine residue of antibody Y bonds to L. 7. A method of inhibiting the growth of a brain tumor in a human in need thereof, the method comprising administering to the human an effective amount of a curcumin derivative having the formula I: Z-L-Y (I) wherein: Z represents: ##STR00007## A represents --CH.sub.2--CH.sub.2-- or --CH.dbd.CH--; L represents --C(O)--(NH).sub.n1--R--(NH).sub.n2--C(O)--; R represents a saturated or unsaturated, branched or unbranched hydrocarbyl chain having a minimum of 3 carbon atoms in the chain; wherein the maximum number of carbon atoms in the chain is 24; and wherein the carbon atoms of the chain can be replaced by at least one heteroatom, wherein the heteroatoms are independently --O-- or --NH.sub.2--, with the proviso that each heteroatom is separated from each other heteroatom by at least two carbon atoms; n1 and n2 independently represent 0 or 1; and Y represents an antibody that binds specifically to the CD68 antigen of a brain tumor cell. 8. The method according to claim 7, wherein A represents --CH.dbd.CH--. 9. The method according to claim 7, wherein n1 and n2 are 0. 10. The method according to claim 7, wherein R represents a saturated, unbranched hydrocarbyl chain. 11. The method according to claim 7, wherein R represents a saturated, unbranched hydrocarbyl chain having a minimum of 3 and a maximum of 8 carbon atoms. 12. The method according to claim 7, wherein a lysine residue of antibody Y bonds to L. 13. The method according to claim 7, wherein the tumor is a glioblastoma. 14. The method according to claim 7, further comprising, after substantially all tumor cells have been eliminated, administering an amount of a solubilized form of curcumin effective to slow the growth of any remaining tumor cells. 15. The method according to claim 7, further comprising administering at least one additional anti-cancer chemotherapeutic agent selected from the group consisting of carboplatin, cisplatin, cyclophosphamide, docetaxel, doxorubicin, erbitux, erlotinib, etoposide, fluorouracil, gemcitabine, herceptin, imatinib, irinotecan mesylate, irinotecan, methotrexate, paclitaxel, sorafinib, sunitinib, topotecan, vinblastine, and vincristine. 16. The method according to claim 7, further comprising administering at least one additional anti-cancer chemotherapeutic agent selected from the group consisting of Temodar, Avastin, Matulane, Gliadel, and BiCNU. 17. The method according to claim 7, wherein the brain tumor originated in the brain or is a metastasis to the brain that originated elsewhere.

Details for Patent 9,446,145

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2029-12-02
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2029-12-02
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2029-12-02
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2029-12-02
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2029-12-02